Navigation Links
Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
Date:8/23/2010

SAN DIEGO, Aug. 24 /PRNewswire/ -- In a recent study presented at the American Association of Physicists in Medicine (AAPM) 52nd Annual Meeting, researchers at the University of Washington showed that 18FDG dose for Positron Emission Mammography (PEM) may be reduced by as much as 70% without altering image quality.

PEM scanners are high-resolution breast PET systems that show the location as well as the metabolic phase of a lesion.  The metabolic view assists physicians to make the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term "specificity."  PEM is different than x-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease in a patient already diagnosed with a primary breast cancer.

"We have several tools to help us make better patient care choices.  Mammography is our primary screening tool.  PEM is used in women with known breast cancer in order to plan treatment," said Wendie Berg, MD, Breast Imaging Radiologist, Lutherville, MD.  "Radiation for treatment of breast cancer uses doses which are roughly 5000 times higher than a diagnostic PEM study.  Minimizing radiation dose is still important for any patient, and we can likely cut the dose of PEM in half, but the benefit to proper treatment exceeds the still low risk from the radiation dose of PEM."

Dr. Lawrence MacDonald, Research Assistant Professor in the Department of Radiology at the University of Washington, and his team presented results of a study to detect lesions with very low doses of radiation using the Naviscan PEM scanner.  Preliminary results using phantom images suggest that PEM lesion detection can be reduced down to approximately 3 mCi injected dose of 18FDG or 3 to 4 times lower than the dose commonly used in clinical practice, while maintaining lesion detectability.  These results are the basis of an ongoing clinical trial at Swedish Cancer Institute with the goal of determining the optimized dose levels of FDG required to produce high quality PEM images in patients with breast cancer.

"Naviscan believes that the radiation dose to patients who undergo PEM can be cut at least in half, if not more as suggested by the University of Washington study," said Judy Kalinyak, MD, Medical Director, Naviscan, Inc.  "Our site in Japan is already injecting 5 mCi of FDG compared to the 10 mCi in the US and a recently published abstract in The Journal of Nuclear Medicine further validates the reduction in dose down to 5 mCi."

Results from a recent presentation at the Society of Nuclear Medicine on findings from an NIH-sponsored clinical study comparing PEM with breast MRI further demonstrate PEM's clinical appropriateness. This multi-site study (NIH Grant 5R44CA103102) of hundreds of women with newly diagnosed breast cancer shows that PEM demonstrated a six percent improvement in specificity at comparably high sensitivity, and also recommended fewer unnecessary biopsies. These results are particularly significant for women who cannot tolerate an MRI exam and require an alternate imaging tool. The study is slated for publication in the December issue of the journal Radiology.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com


'/>"/>
SOURCE Naviscan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Care360™ EHR Module Receives Preliminary ARRA IFR Stage 1 Certification
2. Lilly Halts Development of Semagacestat for Alzheimers Disease Based on Preliminary Results of Phase III Clinical Trials
3. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
5. ISTA Pharmaceuticals Announces Preliminary, Unaudited Revenue of $110.6 Million in 2009
6. Osteotech Announces Preliminary Fourth Quarter 2009 Revenue
7. ATS Medical Announces Preliminary Fourth Quarter 2009 Results
8. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
9. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
10. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
11. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):